Product Details
Place of Origin: China
Brand Name: Sunshine
Certification: ISO,COA
Model Number: 5104-49-4
Payment & Shipping Terms
Minimum Order Quantity: Negotiation
Price: Negotiation
Packaging Details: Aluminum Foil Bag, Drum
Delivery Time: 7-15 days
Payment Terms: T/T, L/C, D/A, Western Union
Supply Ability: TON
CAS NO:: |
5104-49-4 |
Appearance:: |
White To Off-white Crystalline Solid |
Molecular Formula:: |
C15H13FO2 |
Molecular Weight:: |
244.26100 |
EINECS NO:: |
225-827-6 |
MDL NO:: |
MDL NO: MFCD00079303 |
CAS NO:: |
5104-49-4 |
Appearance:: |
White To Off-white Crystalline Solid |
Molecular Formula:: |
C15H13FO2 |
Molecular Weight:: |
244.26100 |
EINECS NO:: |
225-827-6 |
MDL NO:: |
MDL NO: MFCD00079303 |
Product Description:
Product Name: flurbiprofen CAS NO: 5104-49-4
Synonyms:
2-(2-fluoro-4-biphenylyl)propionicacid;
2-fluoro-alpha-methyl-4-biphenylaceticacid;
2-(2-Fluorobiphenyl-4-yl)propionic Acid;
Chemical & Physical Properties:
Appearance: White to off-white crystalline solid
Assay :≥98%
Density: 1.279 g/cm3 (25℃)
Boiling Point: 376℃
Melting Point: 110-112℃(lit.)
Stability: Stable at normal temperatures and pressures
Storage Condition: Keep tightly closed
Water Solubility: 8mg/L(room temperature)
Solubility: Methanol: soluble50mg/mL
Safety Information:
Signal Word: Danger
Symbol: GHS06
Safety Statements: S36/37/39-45
Hazard Class: 6.1(b)
Hazard Codes: T; C
HS Code: 2916399090
Packing Group: III
WGK Germany: 3
RTECS: DU8341000
RIDADR: UN 2811 6.1/PG 2
Risk Statement: R25
Hazard Declaration: H301
Caution Statements: P301 + P310
Flurbiprofen synthesis was originally reported in 1974. During a study of the pharmacological properties of a large number of substituted phenylalkanoic acids, including ibuprofen and ibufenac, the most potent were found to be substituted 2-(4-biphenyl)propionic acids. Further toxicological and pharmacological studies indicated that flurbiprofen possessed the most favorable therapeutic profile, so it was selected for further clinical development. It was not marketed until 1987, when it was introduced as the sodium salt as Ocufen, the first topical NSAID indicated for ophthalmic use in the United States. The indication for Ocufen is the same as that for Profenal—that is, to inhibit intraoperative miosis induced by prostaglandins in cataract surgery.
2-(2-fluoro-4-biphenylyl)propionicacid is anti-inflammatory drug for chronic arthritis and pain, inflammation of Deformation joint disease, and pain after surgery and tooth extraction. Mouse oral LD50 of 140mg/kg, rats 640-800mg/kg.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.